rethinkTHC Search
Menu
Study breakdown

Canada's cannabis legalization was not associated with increased psychosis-related ER visits in Ontario and Alberta

Retrospective CohortStrong evidence
The takeaway

Despite cannabis-induced psychosis ER visits doubling from 2015 to 2019, statistical analysis found no significant jump in visits attributable to Canada's 2018 legalization for either cannabis-induced psychosis or schizophrenia.

Policymakers, psychiatrists, public health researchers, and anyone following cannabis legalization outcomes.

No significant step change in psychosis visits after legalization (p=0.88)

What the researchers found

Cannabis-induced psychosis ED presentations doubled between April 2015 and December 2019. However, SARIMA models found no significant step-function effects of legalization on weekly ED counts for cannabis-induced psychosis (0.34, 95% CI -4.1 to 4.8, p=0.88), schizophrenia (24.34, 95% CI -18.3 to 67.0, p=0.26), alcohol-induced psychosis, or amphetamine-induced psychosis.

Why it matters

One of the strongest fears about cannabis legalization is increased psychosis burden. This large-scale Canadian analysis found no evidence that legalization itself caused a sudden increase, though the ongoing upward trend warrants monitoring.

The numbers in context

5,832 cannabis-induced psychosis visits; 211,661 schizophrenia visits; 10,829 amphetamine-induced psychosis visits; 1,884 alcohol-induced psychosis visits analyzed. None showed significant step changes after October 2018 legalization.

How the study worked

Population-level analysis of ED presentations across Alberta and Ontario from April 2015 to December 2019. Seasonal Autoregressive Integrated Moving Average (SARIMA) models assessed whether the October 2018 Cannabis Act was associated with step changes in weekly ED counts for four ICD-10-defined conditions.

What this study cannot tell us

Only 14 months of post-legalization data. Gradual rollout of retail stores may delay full effects. Administrative data may not capture all psychosis cases. SARIMA models test for step changes, not gradual shifts. Two provinces may not represent all of Canada.

How to read the evidence

Large population-level dataset with appropriate time-series methodology, though limited post-legalization timeframe.

When this study was published

Published in 2022 with data through December 2019, 14 months post-legalization.

The bigger picture

The doubling of cannabis-induced psychosis visits occurred as a gradual trend, not a sudden jump at legalization. This suggests broader factors (increasing use, higher potency, greater diagnostic awareness) rather than legalization per se are driving the increase.

Questions still open

  • Would a longer post-legalization period reveal delayed effects? Does the gradual increase in cannabis-induced psychosis reflect true increased incidence or improved diagnosis? Will the introduction of edibles and concentrates change these trends?

Common questions

Did cannabis legalization increase psychosis in Canada?
Cannabis-induced psychosis ER visits doubled from 2015 to 2019, but this increase was a gradual pre-existing trend, not a sudden jump at legalization. Statistical models found no significant change attributable to the October 2018 Cannabis Act.
Why might the results not show the full picture?
Only 14 months of post-legalization data were available, and cannabis retail stores opened gradually. Longer follow-up with full market maturation may reveal effects not yet detectable.

Read the original research

Associations Between Canada's Cannabis Legalization and Emergency Department Presentations for Transient Cannabis-Induced Psychosis and Schizophrenia Conditions: Ontario and Alberta, 2015-2019.

Canadian journal of psychiatry. Revue canadienne de psychiatrie, 67(8), 616-625

Citation

Callaghan, Russell C; Sanches, Marcos; Murray, Robin M; Konefal, Sarah; Maloney-Hall, Bridget; Kish, Stephen J. (2022). Associations Between Canada's Cannabis Legalization and Emergency Department Presentations for Transient Cannabis-Induced Psychosis and Schizophrenia Conditions: Ontario and Alberta, 2015-2019.. Canadian journal of psychiatry. Revue canadienne de psychiatrie, 67(8), 616-625. https://doi.org/10.1177/07067437211070650

Explore the wider topic